triazoles has been researched along with er-086526 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Akcakanat, A; Arango, NP; Evans, KW; Gonzalez-Angulo, AM; Janku, F; Kim, C; Meric-Bernstam, F; Naing, A; Scott, S; Tripathy, D; Ueno, NT; Yuca, E; Zhao, M | 1 |
1 other study(ies) available for triazoles and er-086526
Article | Year |
---|---|
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Doxorubicin; Female; Furans; Humans; Hydrazines; Ketones; MCF-7 Cells; Mice; Triazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |